Safety of antiepileptic drugs during pregnancy

Expert Opinion on Drug Safety

Volumn 4, Issue 5, 2005, Pages 869-877

  Hunt, Stephen J ^a   Morrow, Jim I ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Antiepileptic drug; Birth defect; Epilepsy; Management; Pregnancy; Teratogenesis

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; VITAMIN K GROUP; ZONISAMIDE;

CLEFT FACE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DRUG CLASSIFICATION; DRUG INDICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; EPILEPSY; EPILEPTIC STATE; FEMALE; HUMAN; MONOTHERAPY; NEURAL TUBE DEFECT; NEWBORN HEMORRHAGIC DISEASE; NONHUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TERATOGENICITY; UROGENITAL TRACT MALFORMATION;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICONVULSANTS; BIPOLAR DISORDER; EPILEPSY; FEMALE; HUMANS; MIGRAINE DISORDERS; PAIN; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 24344438982     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.5.869     Document Type: Review

References (49)

1. HAUSER WA, ANNEGERS JF, ROCCA WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. (1996) 71:576-586.
2. DANSKY LV, FINNELL LV: Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiological and experimental findings spanning three decades; 2: human studies. Reprod. Toxicol. (1991) 5:301-335.
3. OLAFSSON E, HALLGRIMSSON JT, HAUSER WA, LUDVIGSSON P, GUDMUNDSSON G: Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia (1998) 39:887-892.
4. FAIRGRIEVE SD, JACKSON M, JONAS P et al.: Population-based, prospective study of the care of women with epilepsy in pregnancy. Br. Med. J. (2000) 321:674-675.
5. RUSSELL AJ, MACPHERSON H, CAIRNIE V, BRODIE MJ: The care of pregnant women with epilepsy - a survey of obstetricians in Scotland. Seizure (1996) 5:271-277.
6. VINTEN J, ADAB N, KINI U, GORRY J, GREGG J, BAKER GA: Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology (2005) 64:949-953.
7. FINNELL RH, SHIELDS HE, TAYLOR SM et al.: Strain differences in phenobarbital-induced teratogenesis in mice. Teratology (1987) 35:177-185
8. MCELHATTON PR, SULLIVAN FM, TOSELAND PA: Teratogenic activity and metabolism of primidone in the mouse. Epilepsia (1977) 18: 1-11.
9. HOLMES LB, WYSZYNSKI DF, LIEBERMAN E: The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch. Neurol. (2004) 61:673-678.
10. SAMREN EB, VAN DUIJN CM, CHRISTIAENS GC, HOFMAN A, LINDHOUT D: Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. (1999) 46:739-746.
11. HARTSFIELD JK Jr, HOLMES LB, MOREL JG: Phenytoin embryopathy: effect of epoxide hydrolase inhibitor on phenytoin exposure in utero in C57BL/6J mice. Teratology (1983) 28:1-8.
12. FINNELL RH, DANSKY LV: Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod. Toxicol. (1991) 5:281-299
13. HIRSCHBERGER M, KLEINBERG F. Maternal Phenytoin ingestion and congenital abnormalities: report of a case. Am. J. Dis. Child. (1975) 129:984.
14. ARPINO C, BRESCIANINI S, ROBERT E et al.: Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia (2000) 41:1436-1443.
15. HANSON JW, SMITH DW: The fetal hydantoin syndrome. J. Pediatr. (1975) 87:285-290.
16. ROSA FW: Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. (1991) 324:674-677.
17. GRANSTROM ML, HIILESMANN VK: Malformations and minor anomalies in children of epileptic mothers: preliminary results of the prospective Helsinki study. In: Epilepsy, Pregnancy and the Child. Janz D, Dam M, Richens A, Bossi L Helge H and Schmidt D (Eds), Raven Press, NY, USA (1992):251-258.
18. DIAV-CITRIN O, SHECHTMAN S, ARNON J, ORNOY A: Is carbamazepine teratogenic? A Prospective controlled study of 210 pregnancies. Neurology (2001) 57:321-324.
19. SAMREN EB, VAN DUIJN CM, KOCH S et al.: Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia (1997) 38:981-990.
20. KAAJA E, KAAJA R, HIILESMAA V: Major malformations in offspring of women with epilepsy. Neurology. (2003) 60:575-579.
21. FAIELLA A, WERNIG M, CONSALEZ GG et al.: A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum. Mol. Genet. (2000) 22:227-236.
22. DUNCAN S, MERCHO S, LOPES-CENDES I et al.: Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia (2001) 42:750-753.
23. MALM H, KAJANTIE E, KIVIRIKKO S, KAARIAINEN H, PEIPPO M, SOMER M: Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology. (2002) 59:630-633.
24. OMTZIGT JG, LOS FJ, GROBBEE DE et al.: The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology (1992) 42(4 Suppl. 5):119-125.
25. LINDHOUT D, OMTZIGT JG, CORNEL MC: Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology (1992) 42(4 Suppl. 5):111-118.
26. KOCH S, LOSCHE G, JAGER-ROMAN E et al.: Major and minor birth malformations and antiepileptic drugs. Neurology (1992) 42(4 Suppl. 5):83-88.
27. VAJDA FJ, O'BRIEN TJ, HITCHCOCK A et al.: Critical relationship between sodium valproate dose and human teratogenicity results of the Australian register of antiepileptic drugs in pregnancy. J. Clin. Neurosci. (2004) 11:854-8.
28. Committee on Safety of Medicines. Sodium valproate and prescribing in pregnancy. Current Problems in Pharmacovigilance (2003) 29:6.
29. WYSZYNSKI DF, NAMBISAN M, SURVE T, ALSDORF RM, SMITH CR, HOLMES LB: Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology (2005) 64:961-965.
30. ADAB N, JACOBY A, SMITH D, CHADWICK D: Additional educational needs in children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry (2001) 70:15-21.
31. ADAB N, KINI U, VINTEN J et al.: The longer term outcome of children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry (2004) 75:1575-1583.
32. GAILY E, KANTOLA-SORSA E, HIILESMAA V et al.: Normal intelligence in children with prenatal exposure to carbamazepine. Neurology (2004) 13:28-32.
33. ABDULRAZZAQ YM, BASTAKI SM, PADMANABHAN R: Teratogenic effects of vigabatrin in TO mouse fetuses. Teratology (1997) 55:165-176.
34. CUNNINGTON M, TENNIS P: Lamotrigine and the risk of malformations in pregnancy. Neurology (2005) 64:955-960.
35. PETRERE JA, ANDERSON JA: Developmental toxicity studies in mice, rats, and rabbits with the anticonvulsant gabapentin. Fundam. Appl. Toxicol. (1994) 23:585-589.
36. MONTOURIS G: Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav. (2003) 4:310-317.
37. WILTON LV, SHAKIR S: A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia (2002) 43:983-992.
38. LEPPIK IE, GRAM L, DEATON R et al.: Safety of tiagabine: summary of 53 trials. Epilepsy Res. (1999) 33:235-246.
39. OHMAN I, VITOLS S, LUEF G et al.: Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia (2002) 43:1157-1160.
40. BENNETT GD, AMORE BM, FINNELL RH et al.: Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse. Pharmacol. Exp. Ther. (1996) 279:1237-1242.
41. MEISCHENGUISER R, D'GIONO CH, FERRARO SM: Oxcarbazepine in pregnancy, clinical experience in Argentina. Epilepsy Behav. (2004) 5:163-167.
42. ISOHERRANEN N, SPIEGELSTEIN O, BIALER M et al.: Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxopyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia (2003) 44:1280-1288
43. LONG L: Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav. (2003) 4:447-448.
44. HUNT SJ, CRAIG JJ, IRWIN B et al.: Leveciracetam therapy in human pregnancy: preliminary experience from The UK Epilepsy and Pregnancy Register. 26th IBE/ILAE International Epilepsy Congress. Paris, France (2005).
45. KONDO T, KANEKO S, AMANO Y et al.: Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia (1996) 37:1242-1244.
46. OHTAHARA S, YAMATOGI Y: Safety of zonisamide therapy: prospective follow-up survey. Seizure (2004) 13 (Suppl. 1):S50-S55
47. TOMSON T, LINDBOM U, EKQVIST B et al.: Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia (1994) 35:122-130.
48. SCHMIDT D, CANGER R, AVANZINI G et al.: Change of seizure frequency in pregnant epileptic women. J. Neurol. Neurosurg. Psychiatry (1983) 46:751-755.
49. CHOULIKA S, GRABOWSKI E, HOLMES LB: Is antenatal vitamin K prophylaxis needed for pregnant women taking anticonvulsants? Am. J. Obstet. Gynecol. (2004) 190:882-883.